Off-Label Debate Between FDA, Industry To Formally Begin After Election
After years of industry prodding, FDA schedules a two-day public meeting in November to establish direction for off-label regulation, but the agency is already being pulled in multiple directions.
You may also be interested in...
Off-Label Compendia Weaknesses Illustrated By Tarceva Evidence Gaps
Compendia are often critical to reimbursement for oncology sponsors, but University of North Carolina researchers argue in JAMA the system needs to be revamped.
FDA Taps NIH Veteran Corrigan-Curay To Lead Medical Policy Office
Jacqueline Corrigan-Curay joins from the National Heart, Lung and Blood Institute, where she worked on clinical trial initiatives and served as an NIH representative on FDA’s Drug Safety Oversight Board.
Industry's Off-Label Hearing Priorities Taking Shape
Pfizer attorney raises impact on research and other key themes for the upcoming FDA public hearing.